Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries

Abstract

AbstractBackgroundPneumococcal conjugate vaccines (PCVs) provide strong direct protection in children, while limited data are available on their indirect effect on mortality among older age groups. This multi-country study aimed to assess the population-level impact of pediatric PCVs on all-cause pneumonia mortality among ≥5 years of age, and invasive pneumococcal disease (IPD) cases in Chile.MethodsDemographic and mortality data from Argentina, Brazil, Chile, Colombia, and Mexico were collected for various age strata considering the ≥ 5-year-old population, from 2000-2020. IPD cases in Chile were also evaluated. Time series models were employed to evaluate changes in all-cause pneumonia deaths during the post-vaccination period, with other causes of death used as synthetic controls for unrelated temporal trends.ResultsNo significant change in death rates due to all-cause pneumonia was detected following PCV introduction among most age groups and countries. The proportion of IPD cases caused by vaccine serotypes decreased from 29% (2012) to 6% (2022) among ≥65 years in Chile.DiscussionWhile an effect of PCV against pneumonia deaths (a broad clinical definition) was not detected, evidence of indirect PCV impact was observed among vaccine-type-specific IPD cases.